文献速递抗栓抗凝管理

临床医生对直接口服抗凝药治疗非瓣膜性房颤观点与经验的系统综述

A systematic review of clinicians' views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation.
PubMed 文献 · Br J Clin Pharmacol · 2018-09-22

医生在初治患者中因感知疗效等同或优于华法林且安全性更优而首选DOACs,但对过度抗凝管理和观察到的出血率存在担忧。

要点

  • 医生在初治非瓣膜性房颤患者中首选DOACs而非华法林。
  • 首选理由为感知疗效等同或优于华法林且安全性更优。
  • 对过度抗凝管理和观察到的出血率存在担忧。

核心结论

  • 临床医生对DOACs的观点与经验证据基础有限,需进一步研究。

研究设计与样本

  • 系统综述,检索2006年1月至2017年7月发表的英文研究。
  • 纳入报告医生、护士或药师对任一DOAC或作为药物类别观点或经验的研究。
  • 研究仅在美国和欧洲开展,结局报告存在显著异质性。

主要发现

  • 在报告临床医生偏好的研究中,DOACs在初治患者中为首选而非华法林。
  • 首选基于感知疗效证据等同或优于华法林且安全性更优。
  • 其他有利因素包括国际标准化比值不稳定和可能错过预约的患者。
  • 存在对过度抗凝管理和观察到的出血率的担忧。

临床怎么用

  • 临床药师可参考医生对DOACs的偏好认知,在初治非瓣膜性房颤患者中支持DOACs选择。
  • 针对国际标准化比值不稳定或可能错过预约的患者,可考虑DOACs。
  • 需关注医生对过度抗凝管理和出血率的担忧,提供相应药学支持。

局限性

  • 临床医生对DOACs观点的证据基础有限。
  • 纳入研究仅来自欧洲和美国。
  • 研究结局报告存在显著异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: While a plethora of systematic reviews have provided evidence of efficacy, effectiveness and safety of direct-acting oral anticoagulants (DOACs) in the management of nonvalvular atrial fibrillation, there has been little emphasis on clinicians' perspectives. This systematic review aimed to critically appraise, synthesize and present the available evidence of clinicians' views and experiences. METHODS: Studies published in English from January 2006 to July 2017 reporting the views and/or experiences of doctors, nurses or pharmacists on any individual DOAC or as a pharmacological group were included. Studies were assessed for quality by two researchers, data extracted and findings synthesized using a narrative approach. RESULTS: Following exclusion of duplicates, 777 titles, 394 abstracts and 196 studies were screened. Ten studies were included in the review, nine of which were quantitative (cross-sectional surveys) and one qualitative (semistructured interviews), with marked heterogeneity in outcomes reported. Studies were conducted exclusively in Europe and the USA. In those studies reporting clinician preference, DOACs were first choice over warfarin in naïve patients, based on perceptions of evidence of effectiveness equivalent or superior to warfarin and superior safety. Other advantageous factors were in those with an unstable International Normalized Ratio and likely to miss appointments. There were, however, concerns relating to management of over-anticoagulation and experiences of observed bleeding rates. CONCLUSION: There is a limited evidence base of clinicians' perspectives of DOACs, necessitating further research, particularly given the trajectory of increased use worldwide.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Generalova D, Cunningham S, Leslie SJ, et al. A systematic review of clinicians' views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation. Br J Clin Pharmacol. 2018. PMID: 30112826. doi:10.1111/bcp.13739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。